EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudieOpen Access · CC BY 4.0

Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review

Yeganeh Naderi, Maryam Rad, Ali Sadatmoosavi, Elham Khaleghi, Zahra Khorrami, Goli Chamani, Mohammad Shabani iD

Clinical and Experimental Dental Research · 2024

DOI: 10.1002/cre2.882 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Experimental Dental Research, 2024. Verfasst von Yeganeh Naderi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oral and Dental Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran. Hauptthemen laut MEDLINE: Trigeminal Neuralgia, Carbamazepine, Oxcarbazepine, Botulinum Toxins, Type A. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This review aimed to compare the effectiveness of three treatments: BTX A, CBZ, and OXB, in managing trigeminal neuralgia (TN). Material and Methods We conducted a thorough search for research articles related to our issue using specific keywords on several databases, including Cochrane Central Register of Controlled Trials, Science Direct, Scopus, PubMed, Elsevier, Springer Journals, Ovid Medline, EBSCO, and Web of Science. Our focus was on publications from 1965 to 2023.

Results

We retrieved 46 articles from the search and reviewed them carefully. Out of these, we selected 29 articles that met the inclusion criteria. Among the selected articles, 11 investigated the effects of CBZ and OXB, while 18 explored the impact of BTX A on the improvement of TN symptoms. The response rate ranged between 56% and 90.5% for CBZ and between 90.9% and 94% for OXB. The response rate for BTX A ranged between 51.4% and 100%. All these three treatments had a remarkable effect on the improvement of TN. Importantly, findings highlighted that side effects of CBZ and OXB could lead to treatment discontinuation in some cases, whereas BTX A's side effects have been minimal and less frequent.

Conclusions

Consequently, BTX A emerges as a promising alternative for TN treatment. However, additional clinical trials are necessary to validate this finding, and further research is required to establish a standardized protocol for administering BTX A in TN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trigeminal NeuralgiaCarbamazepineOxcarbazepineBotulinum Toxins, Type AHumansTreatment OutcomeNeuromuscular AgentsAnticonvulsants

Stichwörter der Autor:innen

botulinum toxin type Acarbamazepineoxcarbazepinetrigeminal neuralgia

Substanzen

CarbamazepineOxcarbazepineBotulinum Toxins, Type ANeuromuscular AgentsAnticonvulsants

Autor:innen und Institutionen

  • Oral and Dental Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran.
  • Research Center for Modeling in Health, Kerman University of Medical Sciences, Kerman, Iran.
  • Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Science, Tehran, Iran.
  • Department of Dental Medicine, Karolinska Institute, Scandinavian Center for Orofacial Neuroscience (SCON), Huddinge, Sweden.
  • Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.

ORCID-Profile: Mohammad Shabani

Förderung

  • None

Zitieren

APA

Naderi, Y., Rad, M., Sadatmoosavi, A., Khaleghi, E., Khorrami, Z., Chamani, G., & Shabani, M. (2024). Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research. https://doi.org/10.1002/cre2.882

Vancouver

Naderi Y, Rad M, Sadatmoosavi A, Khaleghi E, Khorrami Z, Chamani G, et al. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and Experimental Dental Research. 2024. doi:10.1002/cre2.882

BibTeX
@article{Naderi2024,
  author = {Naderi, Yeganeh and Rad, Maryam and Sadatmoosavi, Ali and Khaleghi, Elham and Khorrami, Zahra and Chamani, Goli and Shabani, Mohammad},
  title = {Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review},
  journal = {Clinical and Experimental Dental Research},
  year = {2024},
  doi = {10.1002/cre2.882}
}
Kostenlos starten →